Portfolio managment:Layout 1 14/1/10 20:10 Page 16
Business
Figure 4
Stages of applying new
technologies Stage 2
Stage 1 Stage 3
Aligning the Technology
Gaining foothold and Maintaining alignment and
Portfolio to maximise
introduction measuring impact
value and impact
Critical factors
• Alignment with key stakeholders • Dealing with reality of success • Delivering value and impact
who are willing to be early and failure consistently
adopters • Managing high expectations • Prioritising activities due to
• Deliver early success stories • Aligning and realigning portfolio demand
showing value and impact to maximise value
PPM tools
• Transparency of workload • Clear and comprehensive • Prioritisation tools
• Alignment with stakeholders – communication on project status • Project/portfolio plans
communication tools • Assessing value and impact • Effective resource management
• Clear work plans to deliver early • Aligning and realigning portfolio – and utilisation
success mid-course adjustments • Standardisation process of
• Balance of work to deliver both delivery
short and long-term value
in two weeks” it is important that the necessarily essary resources are in place to support the down-
considerably longer holistic timescale for campaign stream output from the campaigns themselves is an
completion is comprehended. At completion of the approach that has demonstrated considerable
screening campaign, it is vital for continued value. In addition, manufacturing resource plan-
engagement that feedback on downstream ning techniques are now being developed by some
progress in lead identification/optimisation is pro- of the leading HTS practitioners with the objective
vided to the HTS team responsible for the initial of developing more effective campaign scheduling
identification of the lead series compounds. through the use of sophisticated supply chain man-
Moving to a higher level of organisation, it is ufacturing planning and communication tech-
important that the wider Discovery organisation is niques
9
. While these are ostensibly software proj-
aligned behind providing the necessary internal ects, their successful implementation requires sig-
resources required to establish an HTS campaign nificant change management implementation and
on site. Clearly the nature of the resources will effective communication across disparate groups
vary by the specific instance of campaign but typi- within Discovery and potentially third party sup-
cally these internal resources will include the abili- pliers. This is a role which PPM groups across the
ty to express functional protein at scale, the provi- industry could become intimately involved with in
sion of large numbers of live cells on a just in time the future.
basis, the development of a tractable and robust Outside the immediate communication require-
HTS assay methodology and the availability of the ment, PPM contributes to the overall governance
necessary automation assay lines for assay valida- of installed capability/technology groups at an
tion and operation. Clearly many of the above organisational level. The organisation has made
activities represent projects in their own right. considerable investment in the capabilities of such
Only following the successful completion of each core groups and it is important to comprehend in a
of these activities can the HTS activity itself com- consistent manner whether the investments are
mence. For best use of finite resources, it is impor- delivering what is required of them
tant that the Research Executive can take a bal- This works at a tactical level by providing a sim-
anced view on the tractability of the component ple and clear picture of the overall status of the
elements behind the proposed HTS campaigns. portfolio within the HTS cycle and activities down-
The establishment of a cross Research Area man- stream from it. At a more strategic level, the aggre-
agement committee to shepherd the development gate view of the portfolio across multiple Research
of new campaigns as well as ensuring that the nec- Areas allows the Research Executive to take a
16 Drug Discovery World Winter 2009/10
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88